Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Teams Up With Synthes To Develop and Commercialize Bone Healing Therapies

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug-device company development collaborations are common, but the range, commercial nature and expected duration of the Synthes/Lilly deal is unusual.

You may also be interested in...



Stryker Bets $316 Million It Can Invigorate Orthovita's Biologics Biz

Stryker hopes its sales force heft can push Orthovita's line of synthetic orthobiologics into a better growth position while filling important competitive gaps.

J&J Doubles Down On Orthopedics With Synthes Deal; Takes Lead In Trauma

Johnson & Johnson will control a majority of the orthopedic trauma device market and double its stake in the spinal device field by acquiring Synthes for $21.3 billion under a definitive agreement announced April 27.

Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment

ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel